RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
PR Newswire•17/11/2026•09:18 ET
0
Key Highlights
- ➤RedHill acquired commercialization rights to Rebyota and Clenpiq
- ➤RedHill divested Talicia through two strategic transactions with mid-size pharma companies
- ➤RedHill is expanding its commercial GI portfolio through a roll-up strategy
- ➤RedHill is leveraging lean infrastructure and physician relationships to accelerate growth
- ➤RedHill identified improved operating economics as supporting shareholder value
Expert Statements
Guy Goldberg, Chief Business Officer of RedHill Biopharma
“The strategic evolution of RedHill's business following the successful execution of two strategic transactions with mid-size pharma companies, the divestiture of Talicia and the acquisition of commercialization rights to Rebyota® and Clenpiq®”
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment PR Newswire
Chief Business Officer, Guy Goldberg, discusses the Company's evolution into a more scalable commercial-stage business, opportunities to drive growth across its expanded GI portfolio and its long-term vision for shareholder value
Get started
Create a free account to read the full story.
